New Delhi: Fifty employees of vaccine maker Bharat Biotech have tested positive for COVID-19.
In a tweet, Bharat Biotech’s Joint Managing Director Suchitra Ella said that 50 of our employees are off work due to covid, yet we continue to work under pandemic lockdowns 24×7 for U Flag of India.
Responding to comments over the COVID-19 vaccine Covaxin supply issues, Ella tweeted, ‘Quite disheartening to the teams to hear some states complaining about our intentions. 50 of our employees are off work due to covid, yet we continue to work under pandemic lockdowns 24×7 for U.’
Meanwhile, the Drugs Controller General of India (DGCI) has approved Bharat Biotech’s COVID-19 vaccine Covaxin for phase II/III clinical trial on those aged between two to 18 years.
Covaxin dispatched 10/5/21.18 states have been covered thou in smaller shipments. Quite disheartening to the teams to hear Some states complaining about our intentions. 50 of our employees are off work due to covid, yet we continue to work under pandemic lockdowns 24×7 for U ?? pic.twitter.com/FmQl4vtqXC
— suchitra ella (@SuchitraElla) May 11, 2021
The trial will take place in 525 subjects at various sites, including AIIMS, Delhi, AIIMS, Patna and Meditrina Institute of Medical Sciences, Nagpur. In the trial, the vaccine will be given by intramuscular route in two doses at day 0 and day 28.